Cancer Immunology and Immunotherapy
A section of Cancers (ISSN 2072-6694).
Section Information
Cancer remains a leading cause of death in Western countries, and treatment of advanced stages of the disease is still limited. Discoveries in the field of cancer immunology and progress in immunotherapy as the first line therapy bring the most exciting times for delivering a potential cure for advanced cancer. Understanding the common mechanisms of tumorigenesis, including changes in tumor microenvironment, immune evasion, and antitumor immune responses, is pivotal for further development of novel therapeutics.
Following early discoveries of connection of autoimmune diseases with cancer, recent advances in T cell biology have revolutionized cancer therapy. Most importantly, standard-of-care chemotherapy and radiation effects have also been linked to immune cell-mediated anticancer effects.
Importantly, multiple clinical trials using checkpoint blockade agents, ATC transfer therapies, and cancer vaccines show much better outcomes than the most effective chemotherapeutic agents.
The aim of this Special Section is to publish findings that relate to cancer immunology and therapies based on the immune-targeting. Topics include, but are not limited to:
- checkpoint blockade
- innate immunity
- adaptive responses
- vaccines
- ATC transfer therapy
- immune evasion
- immune switch
- immunosuppression
- tumor microenvironment
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- New Insights in the Role of Myeloid-Derived Suppressor Cells (MDSCs) in Cancer (Deadline: 31 May 2025)
- New Insights of Hematology in Cancer (Deadline: 31 May 2025)
- Prostate Cancer and Inflammation (Deadline: 31 May 2025)
- Targeting the Tumor Microenvironment in Blood Cancer (Deadline: 15 June 2025)
- Recent Advances in Nanomedicine-Based Cancer Immunotherapy (Deadline: 30 June 2025)
- Updates on Immune Checkpoint Inhibitors in Hepatocellular Carcinoma (Deadline: 30 June 2025)
- CAR T Therapy of Solid Cancers: Problems and Progress (Deadline: 30 June 2025)
- Immune-Related Adverse Events in Cancer Immunotherapy (Deadline: 30 June 2025)
- Immunotherapy Approaches in Breast Cancer Treatment (Deadline: 30 June 2025)
- Combination Immunotherapy for Cancer Treatment (Deadline: 10 July 2025)
- Cancers Hijack Immune Surveillance and Tumor Microenvironment Leading to Immune Evasion (Deadline: 31 July 2025)
- Cancer and Immunomediated Inflammatory Diseases (IMIDs) (Deadline: 31 July 2025)
- Inflammation, Immunity, and Cancer Progression: 2nd Edition (Deadline: 1 August 2025)
- Immunotherapy of Glioblastoma (Deadline: 16 August 2025)
- Immunotherapy in Melanoma: Recent Advances and Future Directions (2nd Edition) (Deadline: 31 August 2025)
- Immunomodulation in Cancer Treatment (Deadline: 31 August 2025)
- CAR T-Cell Therapy and Multiple Myeloma (Deadline: 31 August 2025)
- Advances in T-Cell Immunotherapy for Acute Myeloid Leukemia (Deadline: 15 September 2025)
- Advances in the Treatment of Relapsed and Refractory Multiple Myeloma: Novel Agents, Immunotherapies and Beyond: 2nd Edition (Deadline: 15 September 2025)
- Immunotherapy of Non-Small Cell Lung Cancer (Deadline: 20 September 2025)
- Research Progress of Cutaneous Squamous and Basal Cell Carcinomas (Volume II) (Deadline: 20 September 2025)
- Monoclonal Antibodies in Lymphoma (Deadline: 30 September 2025)
- Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplantation (HCT) (Deadline: 30 September 2025)
- The Tumor Microenvironment and Molecular Aberrations Convey Immune Evasion (Volume II) (Deadline: 30 September 2025)
- Merkel Cell Carcinoma: From Molecular Mechanisms to Clinical Therapy—a Selection of Papers from the 8th Nordic/1st European MCC Meeting (Deadline: 30 September 2025)
- Exploring Immunotherapy in Colorectal Cancer (Deadline: 1 October 2025)
- Near-Infrared Photoimmunotherapy for Cancer Treatment: 2nd Edition (Deadline: 10 October 2025)
- Potential Biomarkers in Immune Checkpoint Inhibitors (Deadline: 20 October 2025)
- Cancer Immunotherapy as Part of Precision Clinical Medicine (Deadline: 30 October 2025)
- Cancer Inhibitory Receptors and Related Cancer Immunotherapy (Deadline: 31 October 2025)
- Immune Biomarkers and Checkpoint Inhibitors: Advancing Immunotherapy in Gynecologic Cancers (Deadline: 31 October 2025)
- Neuro-Immune Orchestration in Brain Tumors: From Molecular Signatures to Therapeutic Innovation (Deadline: 1 November 2025)
- Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors (2nd Edition) (Deadline: 20 November 2025)
- New Insights into Cancer Immunotherapy: From Immune Cell to Clinical Practice (Deadline: 30 November 2025)
- Immune Landscape of Renal Cell Carcinoma (Deadline: 30 November 2025)
- Cancer Immunotherapy in Clinical and Translational Research (Deadline: 30 November 2025)
- Immunotherapy in the Management of Hematologic Malignancy (Deadline: 30 November 2025)
- NK Cells in the Tumor Microenvironment: Immunosuppressive Mechanisms and Therapy (Deadline: 5 December 2025)
- Immunotherapy in Urothelial Carcinoma (Deadline: 31 December 2025)
- Immunotherapy in Non-Small Cell Lung Cancers (Deadline: 31 December 2025)
- Innovative Immunotherapies: CAR-T Cell Therapy for Cancers: 2nd Edition (Deadline: 23 January 2026)
- Immune Profiling in Gastrointestinal Cancers: Implications for Precision Immunotherapy (Deadline: 31 January 2026)
- CAR T Cells in Lymphoma and Multiple Myeloma (Deadline: 31 January 2026)
- Neoadjuvant Immunotherapy in Genitourinary Tumors (2nd Edition) (Deadline: 28 February 2026)
- Immunoediting in Cancer Therapies (Deadline: 28 February 2026)
- Immunotherapy for Skin Cancers (Deadline: 10 March 2026)
- Cancer Immunotherapy: Focus on Immune Checkpoint Inhibitors and Immune Modulators (Deadline: 30 March 2026)
- Mitochondrial Metabolism in Cancer Immune Responses (Deadline: 31 March 2026)
- Immune Landscape of Multiple Myeloma (Deadline: 31 March 2026)
- PD-1/PD-L1 Immune Checkpoint Therapy: From Predictive Biomarkers to Noninvasive Imaging 2nd Edition (Deadline: 25 April 2026)
- Immune Microenvironment and Immunotherapy in Malignant Brain Tumors (Deadline: 30 April 2026)
- The Future of Cancer Immunotherapy: Biomarkers, Tumor Microenvironment, and Precision Medicine (Deadline: 31 May 2026)
- Cancer Immunotherapy-Related Adverse Events and Therapy-Related Accelerated Aging (Deadline: 30 September 2026)
- Immunotherapy with Checkpoint Inhibitors for Non-Small-Cell Lung Cancer (2nd Edition) (Deadline: 30 December 2026)
Topical Collections
Following topical collections within this section are currently open for submissions:
